Secukinumab - Latest Advances

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

Journal: mAbs

Published: October 19, 2025

Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approach.

Journal: The Journal of rheumatology

Published: October 15, 2025

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence.

Journal: The Journal of rheumatology

Published: October 15, 2025

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.

Journal: Cancer biology & medicine

Published: October 13, 2025

Concomitant treatment of secukinumab and ofatumumab in a psoriasis patient with multiple sclerosis.

Journal: Italian journal of dermatology and venereology

Published: October 01, 2025

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Journal: The Journal of dermatological treatment

Published: September 24, 2025

Secukinumab-induced erythema multiforme-like drug eruption in generalized pustular psoriasis: a case report and literature review.

Journal: European journal of dermatology : EJD

Published: September 18, 2025

Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.

Journal: The Journal of rheumatology

Published: September 15, 2025

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.

Journal: Indian journal of dermatology

Published: September 08, 2025

Risk of Ophthalmologic Comorbidities in Hidradenitis Suppurativa Patients.

Journal: Ocular immunology and inflammation

Published: September 04, 2025

Unveiling serine protease activity profiles in Netherton syndrome skin across clinical subtypes by non-invasive analysis.

Journal: American journal of physiology. Cell physiology

Published: September 04, 2025

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.

Journal: JAMA dermatology

Published: September 03, 2025

Filters

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

IL-17A complexes with therapeutic antibodies exhibit distinct size distributions, potentially contributing to clinically observed immunogenicity.

Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approach.

Predicting treatment outcomes in patients with psoriatic arthritis or axial spondyloarthritis: An artificial intelligence-driven approach.

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence.

Multicenter Study of Secukinumab Uptitration in Axial Spondyloarthritis: Real-World Evidence.

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash: preclinical and clinical responses.

Concomitant treatment of secukinumab and ofatumumab in a psoriasis patient with multiple sclerosis.

Concomitant treatment of secukinumab and ofatumumab in a psoriasis patient with multiple sclerosis.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Psoriasis severity, comorbidity burden, and biologic therapy: a multicenter observational study using the Charlson Comorbidity Index.

Secukinumab-induced erythema multiforme-like drug eruption in generalized pustular psoriasis: a case report and literature review.

Secukinumab-induced erythema multiforme-like drug eruption in generalized pustular psoriasis: a case report and literature review.

Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.

Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting.

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.

Evaluation of Short-to-medium Term Efficacy of Guselkumab and Secukinumab in Overweight and Obese Patients with Moderate to Severe Plaque Psoriasis: A 24-Week Single-center Retrospective Study.

Risk of Ophthalmologic Comorbidities in Hidradenitis Suppurativa Patients.

Risk of Ophthalmologic Comorbidities in Hidradenitis Suppurativa Patients.

Unveiling serine protease activity profiles in Netherton syndrome skin across clinical subtypes by non-invasive analysis.

Unveiling serine protease activity profiles in Netherton syndrome skin across clinical subtypes by non-invasive analysis.

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.

Interleukin-17 Inhibitors and Early Major Adverse Cardiovascular Events.